Abstract

Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation are provided. In particular, a method of treating choroidal neovascularisation in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a mineralocorticoid receptor antagonist is provided.

IPC Classes  ?

• A61K 31/585 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 27/02 - Ophthalmic agents

Abstract

A PTGDR-1 antagonist, a PTGDR-2 antagonist, a dual PTGDR-1/PTGDR-1 antagonist, or a combination of PTGDR-1 antagonist and PTGDR-2 antagonist, and pharmaceutical compositions containing them, are provided to patients in need thereof to prevent or treat disease including systemic lupus erythematosus (SLE).

IPC Classes  ?

• A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole

Abstract

The present invention relates to the treatment of Dengue virus infection. To gain insight into the molecular and cellular function of the DENV RC, the inventors generated a tagged NS1 DENV replicon in order to identify associated host proteins during active viral replication. This allowed an unprecedented mapping of the NS1-host interactome in a relevant system and the identification of cellular modules targeted by the DENV RC. By combining these proteomics data with gene silencing experiments, they identified a set of Host Dependency Factors (HDFs) and Host Restriction Factors (HRFs) that critically impact DENV infection. More they tested the NGI-1 molecule for its OST complex inhibition properties and showed that this molecule can be used to treat Dengue virus infection. Thus, the invention relates to an inhibitor of the OST complex and/or of the CCT complex and/or of RACK1 for use in the treatment of dengue virus infection in a subject in need thereof.

IPC Classes  ?

• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to methods and pharmaceutical compositions for the treatment of choroddal neovascularisation. In particular, the present invention relates to a method of treating choroidial neovascularisation in a subject in need thereof comprising administering to the subject of therapeutically effective amount of a mineralocorticoid receptor antagonist.

IPC Classes  ?

• A61K 31/585 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 27/02 - Ophthalmic agents
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets

Abstract

The present invention relates to methods and pharmaceutical compositions of inducing immune tolerance by mucosal vaccination with Fc-coupled antigens. In particular, the present invention relates to a method for inducing tolerance to one antigen of interest in a subject in need thereof, comprising the mucosal administration to the subject of a therapeutically effective amount of a recombinant chimeric construct comprising a FcRn targeting moiety and an antigen-containing moiety.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

The invention relates to vaccine compositions for treating and/or preventing infections by a bacterium of the Chlamydiaceae family, said compositions comprising bacteria of the Chlamydiaceae family, which have been previously treated by at least one peptidoglycan inhibitor, or extracts of said treated bacteria.

IPC Classes  ?

• A61K 39/118 - Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
• A61P 31/04 - Antibacterial agents
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The application relates to means for diagnosing, predicting or monitoring Pneumocystis pneumonia (PCP). The means of the application are also suitable for determining or predicting the efficacy of a drug or treatment against PCP in a human patient. The means of involve the detection and/or quantification, more particularly the quantification, of the RNA transcripts of two different P. jirovecii mitochondrial genes. The first of said two P. jirovecii mitochondrial genes is the P. jirovecii gene, the sequence of which codes for the Cytb protein or the P. jirovecii mitochondrial Small Sub-Unit (mtSSU) gene. The second of said two P. jirovecii mitochondrial genes is a P. jirovecii gene, the sequence of which transcribes into a P. jirovecii ribosomal RNA, e.g., be the mitochondrial P. jirovecii Large Sub-Unit (mtLSU) gene.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C40B 40/08 - Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

In the field of obesity related disease, identification of patients with nonalcoholic steatohepatitis (NASH) would be useful to counsel them more intensively on diet and lifestyle changes and propose new pharmacological treatments. As a consequence, the inventors worked on a method for post-processing images of a region of interest of the liver for reconstructing a map of the internal magnetic susceptibility by using a Bayesian regularization approach to inverse the internal magnetic field. Such method can be implemented on computer and provides better results than other known methods for obesity related disease. This method may be applied for predicting that a subject is at risk of suffering from such disease, diagnosing a disease, identifying a therapeutic or a biomarker and screening compounds useful as a medicine.

IPC Classes  ?

• G06K 9/00 - Methods or arrangements for reading or recognising printed or written characters or for recognising patterns, e.g. fingerprints
• G01V 3/08 - Electric or magnetic prospecting or detectingMeasuring magnetic field characteristics of the earth, e.g. declination or deviation operating with magnetic or electric fields produced or modified by objects or geological structures or by detecting devices
• G06T 7/00 - Image analysis
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
• G01R 33/561 - Image enhancement or correction, e.g. subtraction or averaging techniques by reduction of the scanning time, i.e. fast acquiring systems, e.g. using echo-planar pulse sequences
• G01R 33/565 - Correction of image distortions, e.g. due to magnetic field inhomogeneities

Abstract

The invention relates to vaccine compositions for treating and/or preventing infections by a bacterium of the Chlamydiaceae family, said compositions comprising bacteria of the Chlamydiaceae family, which have been previously treated by at least one peptidoglycan inhibitor, or extracts of said treated bacteria.

IPC Classes  ?

• A61K 39/118 - Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
• A61P 31/04 - Antibacterial agents
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention concerns a microfluidic chip, in particular for cell culture, this chip comprising: - a block (5) made from biocompatible material, - a passage channel (7, 8) made in the block for the passage of cells bathed in a liquid, in particular a nutrient liquid, - a resonant cavity (6) made in the block, connected to the passage channel and comprising walls for containing the cells originating from the passage channel, - a generator (12) generating acoustic waves capable of forming at least one cell aggregate in acoustic levitation in the resonant cavity, - at least one optical emitter (13, 13') capable of illuminating cells in the resonant cavity through at least one wall of the resonant cavity and simultaneous to the generation of acoustic waves in such a way as to structure the at least one aggregate by means of the optical exclusion technique.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• C12M 1/00 - Apparatus for enzymology or microbiology
• G01N 1/40 - Concentrating samples
• G01N 15/00 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials

Abstract

Embodiments of the disclosure relate to the use of an IL-17 pathway inhibitor for treating chronic infections caused by one or more HPVs.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61P 31/20 - Antivirals for DNA viruses

Abstract

The invention relates to a cannula (1) for injecting a fluid (F1) into a body cavity (5), comprising: - a main lumen (LP) for circulating the fluid in a first direction, - an accessory reperfusion lumen (LA) comprising an outlet (20') for discharging the fluid in a second direction, - a device for positioning the cannula in the cavity, the device comprising a stop (41) which can move along an auxiliary lumen (LX) and be deployed in the cavity in order to lock the cannula in position in the cavity, the outlet (30') of the auxiliary lumen being arranged at a distance (d) from the outlet (20') of the accessory reperfusion lumen (LA) such that when the cannula is locked in position in the cavity, the outlet (20') of the accessory reperfusion lumen (LA) is oriented in the cavity such that the collected fluid is discharged in the second direction.

IPC Classes  ?

• A61M 25/00 - CathetersHollow probes
• A61M 25/04 - Holding devices, e.g. on the body in the body, e.g. expansible
• A61M 1/36 - Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation
• A61M 25/01 - Introducing, guiding, advancing, emplacing or holding catheters
• A61M 1/16 - Dialysis systemsArtificial kidneysBlood oxygenators with membranes

Abstract

The present invention relates to mutated factor (FX) polypeptides and uses thereof for the treatment of haemophilia. In particular, the present invention relates to a mutated factor X (FX) polypeptide which comprises a heavy chain wherein at least one amino acid residue at position 401 or 408 is mutated.

IPC Classes  ?

• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
• A61P 7/04 - AntihaemorrhagicsProcoagulantsHaemostatic agentsAntifibrinolytic agents
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

The present invention relates to a system (10) for controlled depositing of a fluid on a substrate (20) and also to a method using the system (10). The system comprises: - a nanoinjector (100), - a mechanical resonator (120) attached to the nanoinjector (100), the mechanical resonator (120) being suitable for detecting contact between the nanoinjector (100) and the substrate (20), - a means for controlling (148) the mechanical resonator (120) comprising: - an exciter means (142) suitable for causing the mechanical resonator (120) to oscillate at an oscillation frequency (fi), - a detector means (144) suitable for detecting the oscillation of the mechanical resonator (120), - a regulator means (146) suitable for adjusting the contact between the nanoinjector (100) and the substrate (20) by controlling the oscillation of the mechanical resonator (120).

IPC Classes  ?

• B29C 64/112 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using individual droplets, e.g. from jetting heads
• B29C 64/209 - HeadsNozzles
• B29C 64/232 - Driving means for motion along the axis orthogonal to the plane of a layer
• B29C 64/393 - Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes

Abstract

The invention relates to a method for manufacturing a superconducting LC-type resonator of the type comprising at least one high-resistivity substrate (1) on which are printed an inductive meander (3), a first so-called lower electrode (41) and a second so-called upper electrode (40) arranged opposite the first so as to form together a capacitor (4) connected in parallel with the inductive meander (3), as well as inductive coupling means (2) dedicated to said resonator, in which a sacrificial aluminium layer is deposited between the first and second electrodes. The invention also relates to the superconducting LC-type resonator thus obtained and to the use of such a resonator for detecting the noise of a millimetre photon.

IPC Classes  ?

• H01P 7/08 - Strip line resonators
• H01P 11/00 - Apparatus or processes specially adapted for manufacturing waveguides or resonators, lines, or other devices of the waveguide type
• H03H 5/00 - One-port networks comprising only passive electrical elements as network components
• H01G 4/33 - Thin- or thick-film capacitors
• H01G 13/06 - Apparatus specially adapted for manufacturing capacitorsProcesses specially adapted for manufacturing capacitors not provided for in groups with provision for removing metal surfaces

Abstract

Among regulatory T cells, natural regulatory T cells (nTregs) ensure the control of self-tolerance and are currently tested in clinical trials in autoimmune diseases and allogeneic hematopoietic stem cell transplantation. Here the inventors show that based on CD39/CD26 markers, the human nTreg population is comprised of 5 major cell subsets each representing a distinct state of maturation. Phenotypic and genetic characteristics of the subsets illustrate the structural parental maturation between subsets which further correlates with expression of regulatory factors. Importantly, the inventors also show that blood nTreg CD39/CD26 profile, remaining constant over a 2year period in healthy persons but varying between individuals, represents a novel biomarker for monitoring chronic diseases, as illustrated in their preliminary study on AI (dermatomyositis, rheumatoid arthritis and leukemias). Accordingly, the present invention relates to the use of CD26 and CD39 as phenotypic markers for assessing maturation of natural Treg cells.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease

Abstract

This invention concerns a new method for differentiating oral neuroectodermal stem cells (CSO-NE), in particular human gingival neuroectodermal stem cells (CSGh), into oligodendrocytes (OL), and their use in the repair of the nervous system, in particular of head injuries.

IPC Classes  ?

• C12N 5/079 - Neural cells
• A61K 35/30 - NervesBrainEyesCorneal cellsCerebrospinal fluidNeuronal stem cellsNeuronal precursor cellsGlial cellsOligodendrocytesSchwann cellsAstrogliaAstrocytesChoroid plexusSpinal cord tissue

Abstract

The present invention concerns a method for inducing differentiation of neuroectodermal oral stem cells, in particular from gingival tissue (GSCs), into osteoblasts by culturing them in an optimal serum-free medium supplemented by necessary components such as platelet lysate, growth hormone, heparin, and/or growth factors. The invention method provides osteoblasts for cell therapy, particularly for the restoration of bone defects in maxillary bones.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

Abstract

The present invention relates to a method for immobilizing a peptide, in particular a CD31-mimetic peptide on a substrate surface, in particular a stent surface, allowing a strong anchoring of said peptide onto a polydopamine polymer functionalized by biorthogonal copper-free chemistry allowing for a standardized density and controlled orientation of said peptide.

IPC Classes  ?

• C07K 17/06 - Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
• C07K 17/14 - Peptides being immobilised on, or in, an inorganic carrier
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61L 31/04 - Macromolecular materials

Abstract

The present invention relates to a method for the modification of the surface of a metallic implantable device for interventional neuroradiology by grafting a CD31 - derived peptide onto the surface of said device, wherein the CD31 -derived peptide consists of a sequence selected from the group consisting of: SEQ ID NO: 2 to 8, SEQ ID NO: 12 to 79, and SEQ ID NO: 81, said method comprising the following steps: a) the coating of a polydopamine layer onto the surface of the device in order to obtain a polydopamine coated surface; b) the modification of the polydopamine coated surface by the addition of a linker comprising at least one reactive moiety chosen from alkyne functions, in order to obtain a modified polydopamine coated surface; and c) the addition of a CD31 -derived peptide comprising an azide terminal group and its reaction with the alkyne function of the linker of step b), in order to obtain a polydopamine coated surface grafted by a CD31-derived peptide.

IPC Classes  ?

• A61L 31/02 - Inorganic materials
• A61L 31/10 - Macromolecular materials
• A61L 31/16 - Biologically active materials, e.g. therapeutic substances

Abstract

regregex vivoin vivoin vitroin vitro, was associated to temporary or lasting remission of disease in spontaneously diabetic NOD mice.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 9/14 - Particulate form, e.g. powders
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/51 - Nanocapsules
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Abstract

Laminar condensation particle counter (1) for submicron aerosol particles detection, comprising a condenser tube (2), a saturator (6) comprising alcohol in a liquid phase, and an aerosol tube (11), which receives air comprising the aerosol particles in a channel, and has an extremity fixed to the temperature-controlled wall of the condenser, the extremity being fixed at a lateral opening of the temperature-controlled wall without protruding in the condenser tube.

IPC Classes  ?

• G01N 15/06 - Investigating concentration of particle suspensions

Abstract

The mucosa is an integrated network of tissues, cells and effector molecules that protect the host from environmental insults and infections. Dysregulation of immunity at mucosal surfaces is thought to lead to mucosal inflammatory diseases such as those affecting the gastrointestinal system (Crohn's disease, ulcerative colitis and irritable bowel syndrome) and respiratory system (asthma, allergy and chronic obstructive pulmonary disorder). Anterior Gradient 2 (AGR2) is a dimeric Protein Disulfide Isomerase (PDI) family member involved in the regulation of protein quality control in the Endoplasmic Reticulum (ER). Its deletion in the mouse intestine increases tissue inflammation and promotes the development of inflammatory bowel disease (IBD). Now the inventors demonstrate that modulation of AGR2 dimer formation yields pro-inflammatory phenotypes notably though the secretion of AGR2 (eAGR2) that promotes monocyte attraction. The inventors show that in IBD and specifically in Crohn's disease, the levels of AGR2 dimerization modulators are selectively deregulated, and this correlates with severity of disease. The inventors thus demonstrate that AGR2 represent systemic alarm signals for pro-inflammatory responses in mucosa. Accordingly, the present invention relates to a method of treating a mucosal inflammatory disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an agent which neutralizes the pro-inflammatory activity of eAGR2.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

The invention relates to a method for the acquisition of an image by an imaging system (20) comprising a matrix of pixels configured to generate an electric response in the event of exposure to an incident light flux travelling through an optical path (21) in which is arranged a wavefront correction element (22), said method comprising the following steps: 1) initiating the exposure of the pixels to the incident light flux; 2) for a plurality of iterations during the exposure: 2.1) non-destructive reading of the electric responses of pixels of a region of interest; 2.2) determining a change in the spatial distribution of pixels in logarithmic mode in relation to the preceding iteration; 2.3) on the basis of this change, establishing a command for the wavefront correction element (22) in order to correct the wavefront; 2.4) configuring the wavefront correction element; and 3) reading the electric responses of the pixels resulting in an image.

IPC Classes  ?

• G02B 26/00 - Optical devices or arrangements for the control of light using movable or deformable optical elements
• G01J 1/00 - Photometry, e.g. photographic exposure meter
• G01J 9/00 - Measuring optical phase differenceDetermining degree of coherenceMeasuring optical wavelength
• H04N 5/374 - Addressed sensors, e.g. MOS or CMOS sensors
• A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
• G06K 9/20 - Image acquisition
• A61B 3/14 - Arrangements specially adapted for eye photography
• H04N 5/232 - Devices for controlling television cameras, e.g. remote control

Abstract

The present invention relates to a method of treating HER2/NEU overexpressing cancers. The inventors discovered that the heme-mediated formation of dimers and in general oligomers of Trastuzumab is associated with an improved complement-mediated cytotoxicity on breast cancer cells. The present data highlight that the sensitivity to heme of Trastuzumab, may have major repercussion on its therapeutic activity. Thus the invention relates to the combination of an HER2/neu antibody with a heme and/or of its oligomers and its therapeutic composition in the HER2/NEU characteristic cancer treatment.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
• A61K 38/42 - HaemoglobinsMyoglobins

Abstract

The invention relates to a heat exchanger (1) comprising several flexible temperature probes (10), which are intended to be placed in contact with an external fluid and to be coupled to means allowing a heat-transfer fluid to be circulated through the flexible temperature probes, which are mounted fluidically in parallel, and which exchange heat with the fluid – a central canal (11), having a bore-section transverse width of centimetre-scale or smaller, – one or more peripheral canals (12), each having the same bore section for the heat-transfer fluid and each formed at least in part by a heat-exchange wall for the exchange of heat between the external fluid and the heat-transfer fluid; – a coupling end piece (13), situated at a distal end (D) of the flexible temperature probe (10) and fluidically coupling the central canal (11) and the peripheral canal or canals (12).

IPC Classes  ?

• F28D 7/12 - Heat-exchange apparatus having stationary tubular conduit assemblies for both heat-exchange media, the media being in contact with different sides of a conduit wall the conduits being arranged one within the other, e.g. concentrically the surrounding tube being closed at one end, i.e. return type
• F28D 7/00 - Heat-exchange apparatus having stationary tubular conduit assemblies for both heat-exchange media, the media being in contact with different sides of a conduit wall
• F28D 21/00 - Heat-exchange apparatus not covered by any of the groups
• F28F 21/06 - Constructions of heat-exchange apparatus characterised by the selection of particular materials of plastics material
• F24T 10/17 - Geothermal collectors with circulation of working fluids through underground channels, the working fluids not coming into direct contact with the ground using tube assemblies suitable for insertion into boreholes in the ground, e.g. geothermal probes using tubes closed at one end, i.e. return-type tubes

Abstract

The present invention relates to nanoparticles, methods and compositions which are suitable for the detection and/or follow-up and/or treatment of type 1 diabetes. In particular, it relates to biocompatible tolerogenic nanoparticles comprising at least: (i) a ligand which can bind to an aryl hydrocarbon receptor (AHR) transcription factor; an (ii) a diabetes autoantigen selected from : insulin, preproinsulin, proinsulin, or an immunologically active fragment thereof The inventors have shown that such biocompatible tolerogenic nanoparticles are efficient for the identification of type-1 diabetes. It has also been shown that they can accumulate into the pancreas, and induce temporary or lasting remission of disease in spontaneously diabetic NOD mice. Kits and compositions are further provided.

IPC Classes  ?

• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 47/52 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

The invention relates to a compound inhibiting the interaction between a Grb14 protein and an insulin receptor of Formula (I) or Formula (II), their salts, solvates, and/or diastereoisomers, for use for therapeutic purposes, in particular for the treatment of insulin resistance, and to pharmaceutical compositions containing such compounds.

IPC Classes  ?

• A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• A61K 31/42 - Oxazoles
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine

Abstract

The structure (10) comprises an elastically deformable body (12) defining at least one network of internal cavities (14), each internal cavity (14) having a closed contour in at least one section of the internal cavity (14). Each internal cavity (14) is able to be pressurized so as to make the elastically deformable body (12) pass from a rest configuration to at least one pressurized configuration. In each pressurized configuration, the elastically deformable body (12) has a macroscopic metric that is distinct from its macroscopic metric in the rest position. In each pressurized configuration, the radius of curvature of an outer surface of the elastically deformable body (12), considered regarding each internal cavity (14) adjacent to the outer surface, is greater than twice the size of the internal cavity (14) adjacent to the outer surface.

IPC Classes  ?

• A47C 4/54 - Inflatable chairs
• A47C 27/10 - Fluid mattresses with two or more independently-fillable chambers
• A45F 3/20 - Water-bottlesMess-tinsCups of flexible materialCollapsible or stackable cups
• A45F 3/00 - Travelling or camp articlesSacks or packs carried on the body
• A47G 9/00 - Bed-coversCounterpanesTravelling rugsSleeping rugsSleeping bagsPillows
• A61B 17/00 - Surgical instruments, devices or methods
• A61M 25/10 - Balloon catheters
• B60R 21/233 - Inflatable members characterised by their shape, construction or spatial configuration comprising a plurality of individual compartmentsInflatable members characterised by their shape, construction or spatial configuration comprising two or more bag-like members, one within the other
• E04H 15/20 - Tents or canopies, in general inflatable, e.g. shaped, strengthened or supported by fluid pressure

Abstract

Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. IgA is mainly produced by the gut associated lymphoid tissue (GALT). Both experimental and clinical data suggest a role of the gut microbiota in this disease. The inventors aimed to determine if an intervention targeting the gut microbiota could impact disease development in a humanized mouse model of IgAN, the α1KI-CD89TG mice. Four- week old mice were divided into two groups to receive either antibiotics or vehicle-control by oral gavage twice a week for eight weeks. Antibiotic treatment efficiently depleted the faecal microbiota, impaired GALT architecture and impacted mouse IgA production. However, while hlgA1 and mIgG serum levels were unchanged, the antibiotic treatment markedly prevented hlgA1 mesangial deposition, glomerular inflammation and the development of proteinuria. This was associated with a significant decrease in circulating hlgA1-mIgG complexes. These data support that use of antibiotics would be suitable for the treatment of immunoglobulin A nephropathy.

IPC Classes  ?

• A61K 38/14 - Peptides containing saccharide radicalsDerivatives thereof
• A61K 38/12 - Cyclic peptides
• A61K 31/65 - Tetracyclines
• A61K 31/18 - Sulfonamides
• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61K 31/4164 - 1,3-Diazoles
• A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins

Abstract

Disclosed herein are methods for treating patients that may develop or already have pre- existing gene therapy neutralizing antibodies by administering a protease that cleaves peptide bonds present in immunoglobulins or by administering a glycosidase that cleaves carbohydrate residues present on immunoglobulins, or other similar enzymatic cleavage of immunoglobulins in vivo. Also disclosed are methods for utilizing IdeS and other immunoglobulin G-degrading enzyme polypeptides for gene therapy treatment of a disease in a patient in need thereof.

IPC Classes  ?

• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61K 39/12 - Viral antigens
• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin

Abstract

The present invention relates to a method for promoting wound healing in a subject suffering from Ectodermal dysplasia in need thereof comprising a step of administering subcutaneously, intradermally or topically to said subject a therapeutically effective amount of a compound which restores the activity of p63. Inventors have performed a primary culture of patient keratinocytes suffering from ectodermal dysplasias with two compounds which restore the activity of p63 (e.g.STIMA-1 and/or PRIMA-1Met). They have shown that there is an important differentiation of the keratinocytes of said patient compared to the cells not treated with these compounds. They observed that the activity of p63 mutated is restored, thus the proliferation and differentiation of keratinocytes from the patient are activated. Moreover, inventors have used PRIMA-1Met by topical application on a young patient suffering from ectodermal dysplasias and shown that said patient presents an improvement on her hand. Typically, severe skin erosions (on hands and feet) are healing when PRIMA-1Met is administered topically on the hand.

IPC Classes  ?

• A61K 31/4748 - QuinolinesIsoquinolines forming part of bridged ring systems
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61P 17/00 - Drugs for dermatological disorders

Abstract

The present invention relates to a compound of the following formula (I): (I). The invention also relates to uses thereof as dye or pigment, notably as a luster pigment,and to areflective or photonic or nanophotonic or optoelectronic deviceand to a metal-like reflective coatingor a metal-like liquid film,comprising a compound of the invention.

IPC Classes  ?

• C07C 39/23 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
• C07C 43/205 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring
• C07C 49/603 - Unsaturated compounds containing a keto group being part of a ring of a six-membered ring, e.g. quinone methides
• C07C 255/07 - Mononitriles
• C07F 7/08 - Compounds having one or more C—Si linkages
• C09B 11/02 - Diaryl- or triarylmethane dyes derived from diarylmethanes
• C09B 11/06 - Hydroxy derivatives of triarylmethanes in which at least one —OH group is bound to an aryl nucleus
• C07C 225/12 - Compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly-bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings with doubly-bound oxygen atoms bound to carbon atoms being part of rings
• C07C 255/40 - Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by doubly-bound oxygen atoms
• C07D 321/00 - Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups
• C09B 23/14 - Styryl dyes
• C09B 57/00 - Other synthetic dyes of known constitution
• C07C 49/753 - Unsaturated compounds containing a keto group being part of a ring containing ether groups, groups, groups, or groups
• C07C 49/747 - Unsaturated compounds containing a keto group being part of a ring containing hydroxy groups containing six-membered aromatic rings

Abstract

The present invention relates to a method for treating brain injury or neurodegenerative disease in a subject in need thereof comprising a step of administering said subject with a therapeutically effective amount of a syndecan-1 agonist. Inventors have shown a different expression pattern of Syndecan-1 between quiescent and activated neural stem cells (NSCs) and demonstrated its role in the proliferation of activated NSCs. They have shown that syndeacan-1 is a marker of proliferative NSCs. Their data highlight the central role of the stem cell microenvironment in the regulation of quiescence in adult neurogenic niches. Finally, inventors unravel the role of Syndecan-1 (Sdc1) in the proliferation of activated NSCs. Interestingly, Sdc1 transcripts, highly enriched in proliferative cells, significantly decreased after BMP4 treatment. To confirm the role of SDC1 in the proliferation of activated NSCs, they performed silencing experiments using siRNA directed against Sdc1. Accordingly, inventors have found new approaches for NSC-based regenerative medicine.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The present invention relates to a compound of the following formula (I): (I). The invention also relates to uses thereof as dye or pigment, notably as a luster pigment. The invention relates also to a reflective or photonic or nanophotonic or optoelectronic device comprising a compound of the invention. The invention relates also to a metal-like reflective coating,a metal-like particle or an organic-based metal-like liquid film comprising a compound of the invention.

IPC Classes  ?

• C07C 211/50 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring having at least two amino groups bound to the carbon skeleton with at least two amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
• C07C 217/08 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
• C07C 217/76 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and etherified hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
• C07C 217/80 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
• C07C 217/84 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
• C07C 217/92 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the nitrogen atom of at least one of the amino groups being further bound to a carbon atom of a six-membered aromatic ring
• C07C 217/94 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
• C07C 255/24 - Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
• C07C 255/26 - Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton containing cyano groups, amino groups and singly-bound oxygen atoms bound to the carbon skeleton
• C07D 321/00 - Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups
• C07D 333/20 - Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
• C07F 7/08 - Compounds having one or more C—Si linkages
• C07F 9/535 - Organo-phosphoranes
• C09B 11/02 - Diaryl- or triarylmethane dyes derived from diarylmethanes
• C09B 11/12 - Amino derivatives of triarylmethanes without any —OH group bound to an aryl nucleus
• C09B 11/16 - Preparation from diarylketones or diarylcarbinols
• C09B 11/28 - Pyronines
• C09B 57/00 - Other synthetic dyes of known constitution

Abstract

The present invention relates to the field of drug administration, in particular the field of in situ postoperative drug administration. Among the many options available to fight cancer, tumor ablation can be one of the most effective one, depending on the case and on the cancer type. However, there are some cases wherein the residual tumoral cells left after the ablation can seed the propagation of a new tumor afterward. The invention provides a way to address this problem and relates to a multilayer patch comprising: - A biocompatible carrier layer, - A first polymeric layer comprising a first drug, and - A second polymeric layer comprising a second drug, wherein the first drug is different from the second drug. Particularly, the inventors tested the invention in case of pancreas cancers whence it proved especially useful.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
• A61K 33/24 - Heavy metalsCompounds thereof
• A61P 35/00 - Antineoplastic agents

Abstract

A device for automatically imaging the capillary blood vessels of a living tissue likely to move, configured for selecting images of the sequence, called 'sharp images', arranged in chronological order of acquisition, shuffling the sharp images, for decorrelating temporally the sharp images, by arranging them in a shuffled order different from the chronological order, realigning spatially the sharp images arranged in the shuffled order, generating a projected image by projection of the pixels of the realigned sharp images, in a stack, the projected values of the pixels forming the projected image being extremal intensity values of the pixels of all the sharp images, the projection of the extremal of intensity values of the pixels rendering all the positions of all erythrocytes of all the sharp images in the projected image.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

222S in biological fluids by means of this sensor.

IPC Classes  ?

• C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions

Abstract

Choroidal neovascularization (CNV) is a major cause of vision loss, due to exudation of intraretinal or subretinal fluid, hemorrhage, or fibrosis at the macula. Neovascularization arising from the choroidal circulation is seen in are age-related macular degeneration (AMD), pathological myopia (PM), choroidits and central serous chorioretinopathy (CSCR). The current anti-VEGF treatments do not induce a total regression of the CNV requiring repeated injections to maintain vision. Moreover, evidence regarding anti-VEGF therapy resistance suggests a need for alternative medicines for the treatment of CNV. Despite the anatomical separation of choroid from vitreous, the inventors surprisingly found that intravitreal of decorin (DCN) is suitable for inhibiting choroidal neovascularisation. In particular, the inventors show an anti-angiogenic effect of DCN on CNV and demonstrate that laser-induced CNV decreased DCN expression in the RPE-Choroid. Accordingly, the present invention relates to a method of treating choroidal neovascularization comprising delivering a therapeutically effective amount of a decorin polypeptide in the vitreous of the eye.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 27/10 - Ophthalmic agents for accommodation disorders, e.g. myopia
• A61P 27/02 - Ophthalmic agents

Abstract

TP53, EGFRSTK11 TP53, EGFRSTK11TP53, STK11EGFREGFR and concluding that the patient has a high probability to achieve a response with an immune checkpoint inhibitor in function of its mutations profile.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The invention relates to methods for predicting the outcome of a patient suffering from prostate cancer or breast cancer and methods for the treatment of prostate cancer or breast cancer. The inventors show that Doublecortin-expressing (DCX+) neural precursors from the central nervous system (CNS) enter the bloodstream, infiltrate prostate tumours and metastasis and differentiate into neo-neurons that contribute to tumour development. In human primary prostate tumours and transgenic mouse cancer tissues, the density of DCX+neural progenitors is strongly associated with tumour aggressiveness, invasion and recurrence. In transgenic cancer mice, oscillations of DCX+neural stem cells in the subventricular zone (SVZ), a neurogenic area of the CNS, were associated with egress of DCX+cells from the SVZ to the bloodstream. These cells then reach the tumour where they initiate neurogenesis. Selective genetic depletion of DCX+cells in mice inhibits the early phases of prostate cancer development, whereas ortho topic transplantation of DCX+cells purified from prostate tumour or brain tissues promotes tumour growth and cancer cell dissemination. These results unveil a unique crosstalk between the CNS and the tumour that drives a process of neurogenesis necessary for prostate cancer development, and indicate a novel neural element of the tumour microenvironment as a potential target for cancer treatment. Thus, the invention relates to a method for predicting the outcome of a patient suffering from prostate cancer and compound targeting DCX+ neural progenitor cells for use in the treatment of prostate cancer.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61P 13/08 - Drugs for disorders of the urinary system of the prostate
• A61P 35/00 - Antineoplastic agents
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

1211C11c11abcc, X2- and L as defined in the claims, or a hydrate or a solvate thereof. Compositions and kits comprising same are also described. Said bis-hydrazone derivatives of formula (I), compositions and kits are useful as drugs, in particular for treating or preventing cancers associated with the Epstein-Barr Virus.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61K 31/47 - QuinolinesIsoquinolines
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 471/04 - Ortho-condensed systems
• A61P 35/00 - Antineoplastic agents

Abstract

vHGRvHH) extending along a second direction (y), different from the first direction; the photoconductive switch further comprising a patterned opaque layer (PML) selectively masking portions of the gaps between the electrodes. Methods and devices for generating and detecting terahertz radiation comprising such photoconductive switches.

IPC Classes  ?

• G01J 3/10 - Arrangements of light sources specially adapted for spectrometry or colorimetry
• G01J 3/42 - Absorption spectrometryDouble-beam spectrometryFlicker spectrometryReflection spectrometry
• G01N 21/3581 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using far infrared lightInvestigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using Terahertz radiation
• G01J 1/42 - Photometry, e.g. photographic exposure meter using electric radiation detectors
• G01J 4/00 - Measuring polarisation of light
• G02F 1/35 - Non-linear optics
• H01L 31/09 - Devices sensitive to infrared, visible or ultra- violet radiation

Abstract

A method for performing spacetime-constrained oblivious transfer between various laboratories of a first party A and various laboratories of a second party B. The method includes providing the spacetime-constrained oblivious transfer to satisfy various conditions. The method further includes encoding, by the laboratories of the first party A, various messages in a quantum state selected from various non-orthogonal quantum states. The method further includes transmitting, by the laboratories of the first party A, the quantum state to a first laboratory of the second party B. The method further includes applying, by the first laboratory of the second party B, a quantum measurement on the quantum state to obtain a classical measurement outcome. The method further includes transmitting, by the first laboratory of the second party B, the classical measurement outcome to the laboratories of the second party B.

IPC Classes  ?

• H04L 9/06 - Arrangements for secret or secure communicationsNetwork security protocols the encryption apparatus using shift registers or memories for blockwise coding, e.g. D.E.S. systems
• H04L 9/08 - Key distribution

Abstract

11111); generating a condition indicator for the or each pair of values of the first and second parameters, the values defining the coordinates of a point in a reference database.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/0484 - Electroencephalography using evoked response
• G06F 16/28 - Databases characterised by their database models, e.g. relational or object models

Abstract

In most cases, cancer chemotherapy and immunotherapy fail to yield durable responses, and complete and permanent regression of established tumors are rare. Here the inventors show that so-called caloric restriction mimetics (CRMs), which are natural or synthetic compounds that pharmacologically mimic the effects of fasting or caloric restriction, can be used to enhance the probability of cancer cure. The administration of several chemically distinct CRMs (such as hydroxycitrate, lipoic acid and the natural polyamine spermidine) led to the complete regression and the induction of protective anticancer immune responses in mouse models. This effect was achieved when CRMs were combined with chemotherapy and immunotherapy targeting the immune checkpoint molecules CTLA-4 and/or PD-l. Hence, caloric restriction and CRMs can be used to sensitize cancers to chemo-immunotherapy.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/132 - Amines, e.g. amantadine having two or more amino groups, e.g. spermidine, putrescine
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
• A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
• A61P 35/00 - Antineoplastic agents
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

The invention relates to the field of ultrasound imaging of the heart. 4D ultrafast ultrasound imaging of the heart is performed and may be used to compute major cardiac echographic Flow and Tissue Doppler index indexes such as E/E', E/A, E'/A' with a single acquisition in a very quick time (e.g. within a heart beat) and in a reproducible way, independently of the experience of the operator.

IPC Classes  ?

• A61B 8/06 - Measuring blood flow
• A61B 8/08 - Clinical applications
• A61B 8/14 - Echo-tomography
• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
• G01S 15/89 - Sonar systems specially adapted for specific applications for mapping or imaging
• G01S 7/52 - Details of systems according to groups , , of systems according to group

Abstract

The invention relates to a non-invasive process for evaluating the quality of one or more dense connective tissue(s) in a patient, comprising the following steps: a) Analyzing the profile of the microrelief of a cutaneous replica of a portion of the skin of said patient by at least one of the following step: a1. visually assessing on picture(s) of said cutaneous replica the line shape and the anisotropy of the lines; and/or a2. Determining, on picture(s) of said cutaneous replica, the roughness index of the microrelief with an optical sensor, b) identifying cutaneous replica of "stage 1", representative of heathy skins, and cutaneous replica of "stage 2" representative of altered skins, a cutaneous replica of stage 2 being indicative of low quality of the one or more dense connective tissue(s) in the patient's body.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to a compound of the following formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, notably for use as a drug, notably in the treatment of a disease caused by mycobacteria, as well as pharmaceutical compositions containing such a compound and a process to prepare such a compound.

IPC Classes  ?

• C07D 471/08 - Bridged systems
• A61P 31/04 - Antibacterial agents
• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine

Abstract

The present application relates to a double-stranded DNA molecule comprising a first double-stranded DNA molecule (1) linked to a second double-stranded DNA molecule (2) by at least one covalent bond which is not a phosphodiester, phosphorothioate, phosphoramidate or phosphordiamidate bond, advantageously by a tether, said tether advantageously being a double-stranded DNA molecule.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

The present invention relates to a compound of the following formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, notably for use as β-lactamase inhibitors, notably in the treatment of a disease caused by gram negative bacteria, in particular enterobacteria, as well as pharmaceutical compositions containing such a compound and a process to prepare such a compound.

IPC Classes  ?

• C07D 471/08 - Bridged systems
• A61P 31/04 - Antibacterial agents
• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine

Abstract

Autophagy is a universal anti-aging mechanism the chronic induction of which can extend the health span and lifespan of mammals. Here the inventors show that triethylenetetramine (TETA), also called trientine, a drug that is approved for the treatment of Wilson disease, can induce autophagy in mouse tissues in vivo. In particular, chronic autophagy stimulation by TETA can improve the metabolic characteristics of mice kept on a high-fat or high-sugar diet without reducing their food uptake, yet attenuating their weight gain. TETA attenuates adioposity, signs of obesity related type-2 diabetes and hepatosteatosis. TETA also mediates hepatoprotective effects against acute ethanol intoxication. Hence, TETA can be considered as a novel autophagy-inducing agent and thus can be used for the treatment of various diseases and in particular for the treatment of obesity, as well as obesity-related comorbidities.

IPC Classes  ?

• A61K 31/132 - Amines, e.g. amantadine having two or more amino groups, e.g. spermidine, putrescine
• A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 3/06 - Antihyperlipidemics
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/08 - Drugs for disorders of the metabolism for glucose homeostasis
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

The present invention relates to the treatment of Dengue virus infection. To gain insight into the molecular and cellular function of the DENV RC, the inventors generated a tagged NS1 DENV replicon in order to identify associated host proteins during active viral replication. This allowed an unprecedented mapping of the NS1-host interactome in a relevant system and the identification of cellular modules targeted by the DENV RC. By combining 10 these proteomics data with gene silencing experiments, they identified a set of Host Dependency Factors (HDFs) and Host Restriction Factors (HRFs) that critically impact DENV infection. More they tested the NGI-1 molecule for its OST complex inhibition properties and showed that this molecule can be used to treat Dengue virus infection. Thus, the invention relates to an inhibitor of the OST complex and/or of the CCT complex and/or of 15 RACK1 for use in the treatment of dengue virus infection in a subject in need thereof.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 31/12 - Antivirals

Abstract

+ regulatory T cells, and therapeutic uses thereof. The inventors here demonstrated the optimal conditions for inducing Foxp3 expression in naive CD3+ CD4+ TCRαβ+ MHCII restricted T following polyclonal or following antigen-specific activation. They also developed an experimental procedure to generate autologous CD8+ T cell lines functionally committed to lyse tumor-antigen specific FOXP3 expressing TCRαβ+ MHCII restricted T cells, pathogenic CD4+ T cells that favour tumor cell immune evasion. In particular, the present invention relates to a method for generating ex vivo MHCII restricted CD4+ Foxp3+ regulatory T cells having the following phenotype: CD3+ CD4+ Foxp3+.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes

Abstract

The invention relates to a method for quantifying the balance of an individual in order to obtain a value that represents the balance of said individual, said method being implemented by a device comprising at least one data processing module, a storage means and a classification module, said method particularly comprising the following steps: time-dependent segmentation of the at least one statokinesigram of an individual in such a way as to generate a plurality of statokinesigram portions; extraction, from the statokinesigram portions, of the values of at least one trajectory parameter; determination of the value of at least two quantifiers, from the trajectory parameters extracted in the extraction step, for each of the statokinesigram portions generated in the segmentation step; and determination of said value representing the balance of the individual on the basis of the values of the quantifiers of each of the statokinesigram portions.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

11out1rcc) applied to the source.

IPC Classes  ?

• H03B 17/00 - Generation of oscillations using a radiation source and a detector

Abstract

11outxout1dd) to introduce a delay (τ), and to apply the delayed acoustic wave to the optomechanical resonator.

IPC Classes  ?

• H03B 17/00 - Generation of oscillations using a radiation source and a detector

Abstract

13455 are amino acid residues or amino acid like structures. The invention also relates to a compound of formula (I) for its use as a Caspase-2 inhibitor and for its therapeutical use. It also concerns the use of a compound of formula (I) as activity base probe to selectively detect Caspase-2 activity.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 14/81 - Protease inhibitors

Abstract

Autophagy is typically activated by starvation, allowing cells and organisms to mobilize their energy reserves. It is known that pharmacological modulation of autophagy represents a therapeutic potential. Here the inventors report that a protein that is released from cells in an unconventional, autophagy-dependent manner, namely, diazepam binding inhibitor (DBI), regulates autophagy. In particular, the inventors demonstrate that DBI inhibits autophagy and that the supply of recombinant DBI to mice enhanced glycolysis, enhanced lipogenesis, and inhibited fatty acid oxidation. The inventors show that neutralisation of DBI by a monoclonal antibody and an active immunization by means of an immunogenic DBI derivative eliciting autoantibodies induce autophagy and lead to metabolic changes that increase starvation-induced weight loss, reduce food intake upon refeeding, and reduce weight gain in response to hypercaloric diets. Accordingly, the present invention relates to methods and pharmaceutical compositions for modulating autophagy based on the modulation of the activity or expression of DBI.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans

Abstract

The present invention relates to the prognostic of cancer and particularly renal cancer. Here, the inventors have investigated the presence and impact of C1q, produced by the macrophages, in the ccRCC TME and showed that it is associated with poor prognosis, particularly in patients with advanced and metastatic tumors. They propose that this is due to the activation of at least the early steps of the complement. Their data provide a novel mechanism of immune modulation of TME in ccRCC that may explain the particularly poor clinical impact of the TME in these tumors. Thus, the invention relates to a method for predicting the survival time of a patient suffering from a cancer by determining the expression level of C1q.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The invention relates to a fluid system for producing extracellular vesicles from producing cells, comprising at least one container, a liquid medium contained by the container and producer cells, characterised in that it also comprises microcarriers suspended in the liquid medium, the majority of the producer cells being adherent to the surface of the microcarriers, and a liquid medium agitator, the agitator and the dimensions of the container being capable of controlling a turbulent flow of the liquid medium in the container.

IPC Classes  ?

• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12M 1/06 - Apparatus for enzymology or microbiology with gas introduction means with agitator, e.g. impeller
• C12M 1/00 - Apparatus for enzymology or microbiology

Abstract

Persistent inflammation is a driving force of fibrosis progression. Mucosal-Associated Invariant T (MAIT) cells are non-conventional T cells that display altered functions during chronic inflammatory diseases. Here, the inventors report a loss of circulating MAIT cells in cirrhotic patients and their hepatic accumulation in an activated phenotype within the fibrotic septa. Using two models of chronic liver injury, the inventors demonstrate that mice enriched in MAIT cells (Vα19TCRTg) show exacerbated liver fibrosis and higher number of hepatic fibrogenic cells than wild type counterparts, whereas MAIT cell-deficient mice (MR1-/-mice) are resistant. The results highlight the profibrogenic functions of MAIT cells and suggest that 1 targeting MAIT cells may constitute an attractive antifibrogenic strategy during chronic liver injury. Accordingly, the present invention relates to a method of treating fibrosis in a patient in need thereof comprising administering to the subject a therapeutically effective amount of an agent capable of inhibiting the activation of MAIT cells.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The invention relates to a porous material in the form of iridium and/or iridium oxide based microspheres, the preparation method thereof, the use thereof as an anode catalyst in a water electrolyser based on a solid polymer electrolyte, also called PEM ("Proton Exchange Membrane" or "Polymer Electrolyte Membrane") water electrolyser, or for manufacturing light-emitting diodes for various electronic devices or for motor vehicles, and a PEM water electrolyser comprising such a material as anode catalyst.

IPC Classes  ?

• C01G 55/00 - Compounds of ruthenium, rhodium, palladium, osmium, iridium, or platinum

Abstract

An easily administrable drug treatment to increase the recanalization rate associated with intravenously t-PA would represent a major advance in the acute ischemic stroke (AIS) management. The inventors demonstrate the presence of NETs network in intracranial thrombus extracted during AIS reperfusion procedures. Thrombi are encapsulated by these NETs network, which confer t-PA resistance. In fact, in presence of DNAse 1, t-PA-induced thrombolysisis accelerated, whereas DNAse alone is inefficient. These results suggest that a co- therapy associating t-PA and DNAse 1 may potentialize t-PA efficacy. Accordingly, the present invention relates to a method of treating an acute ischemic stroke (AIS) in a patient in need thereof comprising administering to the patient a therapeutically effective combination of t-PA and DNAse, wherein administration of the combination results in enhanced therapeutic efficacy relative to the administration of t-PA alone.

IPC Classes  ?

• A61K 38/46 - Hydrolases (3)
• A61K 38/49 - UrokinaseTissue plasminogen activator
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention relates to bisquinolinium derivatives of formula (I): (I) With Y1, Y2, Z1, Z2, X 2- and L as defined in the claims, useful for treating or preventing cancers associated with the Epstein-Barr Virus (EBV-related cancers).

IPC Classes  ?

• A61K 31/4353 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• C07D 401/00 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
• C07D 471/04 - Ortho-condensed systems
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a method for detecting or quantifying human immunodeficiency virus 2 (HIV-2) deoxyribonucleic acid (DNA) in a sample containing DNA, which comprises: a) performing a real-time polymerase chain reaction (PCR) on the sample, or a fraction of same comprising the DNA, with at least two primer and probe assemblies each comprising two primers and one marked probe, respectively, intended for detecting or quantifying HIV-2 DNA, in which at least one of the assemblies is chosen from the group made up of: an assembly comprising a primer comprising or consisting of a sequence of SEQ ID NO.: 1 or a sequence that is at least 90% identical with SEQ ID NO.: 1, a primer comprising or consisting of a sequence of SEQ ID NO.: 2 or a sequence that is 90% identical with SEQ ID NO.: 2 or the complements of these sequences, and a marked probe comprising or consisting of a sequence of SEQ ID NO.: 3, or a sequence that is at least 90% identical with SEQ ID NO.: 3 or the complement of these sequences, and an assembly comprising a primer comprising or consisting of a sequence of SEQ ID NO.: 4 or a sequence that is at least 90% identical with SEQ ID NO.: 4, a primer comprising or consisting of a sequence of SEQ ID NO.: 5 or a sequence that is at least 90% identical with SEQ ID NO.: 5 or the complements of these sequences, and a marked probe comprising or consisting of a sequence of SEQ ID NO.: 6, or a sequence that is at least 90% identical with SEQ ID NO.: 6 or the complement of these sequences; and b) determining from same the presence or absence and/or the amount of HIV-2 DNA in the biological sample.

IPC Classes  ?

• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage

Abstract

The present invention relates to methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion. In particular, the present invention relates to a method of treating retinal capillary non-perfusion in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a ROCK inhibitor.

IPC Classes  ?

• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/4409 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61P 27/02 - Ophthalmic agents

Abstract

The invention relates to the extraction of organic compounds from mixtures of said compounds with water, using a nanoporous carbon membrane. The invention can be used in any field where it is desired to separate an organic compound of interest from water, such as the drying of alcohols or alkanes.

IPC Classes  ?

• C07C 29/76 - SeparationPurificationStabilisationUse of additives by physical treatment
• C07C 31/08 - Ethanol
• C07C 31/12 - Monohydroxylic acyclic alcohols containing four carbon atoms
• C07B 63/00 - PurificationSeparation specially adapted for the purpose of recovering organic compoundsStabilisationUse of additives
• B01D 61/00 - Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltrationApparatus, accessories or auxiliary operations specially adapted therefor
• C07C 7/144 - Purification, separation or stabilisation of hydrocarbonsUse of additives using membranes, e.g. selective permeation

Abstract

The present invention relates to SCGB1A1 polymorphism for the prediction and therapy or prevention of primary graft dysfunction (PGD). The outcome following lung transplantation is currently limited by the occurrence of PGD, a serious immediate postoperative complication that is a direct consequence of ischemia-reperfusion injury. The inventors showed that the presence of a AG genotype in SCGB1A1 gene (G38A polymorphism) in the donor was associated with a decreased frequency of PGD in the recipient after lung transplantation. In particular, the present invention relates to a method of identifying lungs harvested from a donor and to be grafted to a recipient, having or at risk of having or developing a primary graft dysfunction (PGD), comprising determining, in a sample obtained from said donor or from said lungs, the presence or absence of a single nucleotide polymorphism (SNP) located in SCGB1A1 gene.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

Following a prospective clinical study that includes 242 patients, the inventors show that hepatocyte-derived MV levels predicted transplantation-free survival at 6 months in univariate analysis. In multivariate analysis, this association was shown to be independent of Child-Pugh and of MELD score. Thus the present invention thus relates to a method of predicting the transplantation-free survival time of a patient suffering from cirrhosis comprising determining the level of hepatocyte-derived microvesicles (e.g. by an ELISA assay) in a blood sample obtained from the patient.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention relates to a compound that inhibits interaction between a Grb14 protein and an insulin receptor, of formula (I) or of formula (II), the salts, solvates and/or diastereoisomers thereof, for use for therapeutic purposes, in particular for the treatment of insulin resistance, and pharmaceutical compositions containing such compounds.

IPC Classes  ?

• A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
• A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• C07D 261/16 - Benzene-sulfonamido isoxazoles
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

Plasma levels of different sub-populations of microvesicles (endothelial, leukocyte, platelet and hepatocyte) were measured by flow cytometry or ELISA / filtration on blood samples from 125 patients with cirrhosis, for which 36 of them were diagnosed with HCC at inclusion. The inventors show that the levels of microvesicles of endothelial origin (CD62E +) could predict the occurrence of HCC in patients with cirrhosis. Therefore the present invention relates to a method for determining whether a patient suffering from cirrhosis is at risk of having or developing hepatocellular carcinoma comprising determining the level of endothelial-derived microvesicles (e.g. by flow cytometry) in a blood sample obtained from the patient.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention relates to the field of acoustoelectric and acoustooptical imaging methods. It is known a specific example of an acoustoelectric imaging method, in which focused ultrasonic waves are emitted so as to form an image of the current, line by line. However, the acquisition process disclosed is slow, and all the more so because, as the resulting electrical signals are very weak, a high level of averaging is required. Low frame rates are therefore obtained. That is why the inventors worked on an imaging method with improved contrast and resolution. The present invention proposes a method for imaging a medium (10) wherein ultrasound contrast agents (12) are present.

IPC Classes  ?

• A61B 8/14 - Echo-tomography
• A61B 8/08 - Clinical applications

Abstract

Thrombosis is the main cause of morbidity and mortality in patients with JAK2V617F positive myeloproliferative neoplasms (MPN). Recent works reported the presence of JAK2V617F in endothelial cells in some MPN patients. Here, the inventors show that JAK2V617F endothelial cells promote thrombosis through induction of endothelial P-selectin expression and thus demonstrate that P-selectin blockade was sufficient to reduce the increased propensity of thrombosis. Accordingly the present invention relates to a method of treating thrombosis in a patient suffering from a myeloproliferative neoplasm comprising administering to the patient a therapeutically effective amount of a P-selectin antagonist.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors

Abstract

The invention relates to a method for obtaining a numerical model, the numerical model associating at least one objective measurement to a subjective sensation, the method comprising the steps of: a) imaging the at least one area of the brain by using unfocused waves produced by a transcranial ultrasound probe (20), to obtain at least one acquired image of the activity of the area, b) evaluating a physical quantity representative of the activity of the at least one area based on the acquired images, to obtain at least one objective measurement, c) obtaining from the subject at least one numerical value representative of a subjective sensation, and d) determining the numerical model by using the obtained objective measurement and the obtained numerical value.

IPC Classes  ?

• G09B 23/28 - Models for scientific, medical, or mathematical purposes, e.g. full-sized device for demonstration purposes for medicine
• A61B 8/08 - Clinical applications
• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• A61B 8/06 - Measuring blood flow
• G06T 7/00 - Image analysis

Abstract

The invention relates to a method for designing a flexible blade or an articulated rigid blade with one or more torsion springs, for a wind turbine or a water turbine, the flexible blade being designed to passively control the pitch angle of the wind turbine or of the water turbine during operation, the method comprising the following steps: a) receiving the known geometric profile; b) determining a change in the optimal pitch angle, 0o opt rigid, as a function of the specific speed λ; c) determining the local behaviour of the flexible blade or of the articulated blade and local ratios relating to the aerodynamic loading and to the centrifugal force being exerted on the blade; d) determining local values of the bending modulus B of the flexible blade/the stiffness of the torsion spring and of the mass density p of the blade; and e) providing information relating to the selection of the material.

IPC Classes  ?

• F03D 1/06 - Rotors

Abstract

Blockade of immune checkpoints is one of the most promising approaches for activating therapeutic antitumor immunity. However, the overall benefits of checkpoint blockade cancer immunotherapy vary among individuals. The present inventors demonstrated that a specific single nucleotide polymorphism in the KIT gene is associated with a decrease in intra-tumor CD8 infiltrates. Patients presenting this polymorphism present a low intra-tumor immune adaptive response and treating these patients with a checkpoint blockade cancer immunotherapy would thus be useless. Accordingly the present invention relates to a checkpoint blockade cancer immunotherapy agent for use in a method for treating cancer in an individual who does not display the KIT polymorphism consisting of M541L (KITL541). The present invention further relates to an method for predicting the response of a patient suffering from cancer to a checkpoint blockade cancer immunotherapy by detecting the presence of the M541L KIT polymorphism in a biological sample (such as a tumor sample).

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention relates to methods for assessing the severity of cancer by measuring the expression level of TIM-3 in a tumour sample. The present inventors have determined that the expression of TIM-3 (T-cell immunoglobulin and mucin-domain containing-3) can be correlated with the prognosis and with the responsiveness to treatment of patients suffering from solid cancer. They have particularly demonstrated that the specific ratio of the expression level of TIM-3 to the expression level of a biomarker of the adaptive immune response within the tumour is extremely predictive of patients' survival. Thus, the present invention relates to methods for determining the prognosis patients suffering from a solid cancer by determining the ratio of the expression level of TIM-3 to the expression level of a biomarker of the adaptive immune response in a tumour tissue sample obtained from said patient. Typically, these expression levels are determined by immunohistochemistry.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

Blockade of immune checkpoints is one of the most promising approaches for activating therapeutic antitumor immunity. However, the overall benefits of checkpoint blockade cancer immunotherapy vary among individuals. The present inventors have indeed demonstrated that MET-mutated patients have a better adaptive immune response than non-MET-mutated patients. Accordingly, MET-mutated patients are more likely to respond to a checkpoint blockade cancer. Accordingly, the present invention relates to a method for predicting the response of a patient suffering from cancer to a checkpoint blockade cancer immunotherapy, by determining if the MET gene is mutated in a tumor sample of said patient, wherein a mutation of the MET gene is predictive of a response to the checkpoint blockade cancer immunotherapy.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI ) for treating a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 2 hours to the subject, preferably during at least 4 to 6 hours.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to methods and pharmaceutical compositions for the treatment of myeloproliferative disorders in patients presenting a dysregulation of the JAK2-STAT signalling pathway. Using MPN mouse model and clonogenic methyl-cellulose cultures of patient progenitors, the inventors demonstrate that combining ARS with IFN improves most of the benefits provided by IFN alone during MPN treatment. In particular, the present invention relates to a method of treating a myeloproliferative disorder in a patient presenting a dysregulation of the JAK2-STAT signalling pathway comprising administering to the patient a therapeutically effective combination of an interferon polypeptide and an arsenic compound.

IPC Classes  ?

• A61K 33/36 - ArsenicCompounds thereof
• A61K 38/21 - Interferons

Abstract

The present invention relates to a method for investigating cerebral blood flow in a subject comprising the steps consisting of: (a)subjecting the subject to at least one stimulationperiod inducing activation of a cortical region, while simultaneously performing functional magnetic resonance imaging (fMRI) data acquisition; (b)processing imaging data acquired at step (a) in order to determine the kineticsof the cerebral blood flow (CBF) variation associated with the neural activation of said primary cortical region. Surprisingly, the inventors have shown that the kinetics of the blood flow variation was altered in subjects suffering from a cerebral small vascular disease (CSVD). The results of the inventors provide evidence that the slope of the functional hyperemic response can be used as a biomarker of NVC alterations at early stages of CSVD, in particular at early stages of CADASIL.

IPC Classes  ?

• A61B 5/026 - Measuring blood flow
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G01R 33/48 - NMR imaging systems

Abstract

The present invention relates to a compound of the following formula (I). The invention also relates to uses thereof as a chromophore as such or for building pigments displaying special optical effects, including metal-like reflection.

IPC Classes  ?

• C07D 321/00 - Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups
• C07C 43/205 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring
• C07C 211/50 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring having at least two amino groups bound to the carbon skeleton with at least two amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
• C07C 211/52 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
• C07C 217/76 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and etherified hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
• C07C 217/80 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
• C07C 217/84 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
• C07C 217/94 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
• C07D 471/04 - Ortho-condensed systems
• C07D 209/88 - CarbazolesHydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
• C07F 7/08 - Compounds having one or more C—Si linkages
• C09B 11/02 - Diaryl- or triarylmethane dyes derived from diarylmethanes
• C09B 11/06 - Hydroxy derivatives of triarylmethanes in which at least one —OH group is bound to an aryl nucleus
• C09B 11/12 - Amino derivatives of triarylmethanes without any —OH group bound to an aryl nucleus
• C09B 11/22 - Amino derivatives of triarylmethanes containing —OH groups bound to an aryl nucleus
• C07D 295/135 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Abstract

The present invention relates to a cylindrical-shaped device (51) of electrochemical cells (C(i,j)), mainly characterized in that it comprises: - a stack of three layers of electrodes (1, 2, 3) with related track transfers (12, 22, 32), said layers forming a reference-electrode layer (2), a counter-electrode layer (3) and a working-electrode layer (1), the electrodes of the three layers being superimposed at least in part, and, - a plurality of cylindrical holes (40) passing through the superimposed electrodes (21, 31) of the reference-electrode layer (2) and of the counter-electrode layer (3), these cylindrical holes (40) being blocked by the working-electrode layer (1) and thus constituting a volume (43) forming said electrochemical cells (C(i,j)) of which the side cell wall comprises the reference electrodes and the counter electrodes, and the bottom of the cells comprises the working electrodes (11) in the shape of a disc, the radius of the working electrode being greater than twice the height of the electrodes of the side wall of the cell, said electrochemical cells (C(i,j)) being arranged according to a pattern comprising N rows of index i, and M columns of index j of cells, with N being an integer greater than or equal to 1 and M being an integer greater than or equal to 1, such that if N is equal to 1, then M is greater than or equal to 2, and if M is equal to 1, then N is greater than or equal to 2, wherein: - the cells (C(i,j)) of a row i comprise a common working electrode that electrically connects said cells of row i, - the cells (C(i,j)) of a column j comprise a common reference electrode and a common counter electrode that electrically connect said cells of column j.

IPC Classes  ?

• G01N 27/27 - Association of two or more measuring systems or cells, each measuring a different parameter, where the measurement results may be either used independently, the systems or cells being physically associated, or combined to produce a value for a further parameter
• G01N 27/30 - Electrodes, e.g. test electrodesHalf-cells

Abstract

The present invention relates to methods and kits for diagnosing Idiopathic steroid sensitive nephrotic syndrome. The inventors showed that idiopathic nephrotic syndrome (INS) patients display a significant plasma level of anti-UCHL1 IgG that target the podocytes. Based on the correlation between the plasma level of anti UCHL1 IgG and proteinuria, they suggested that anti UCHL1 IgG plays a central role in the development of massive proteinuria. In particular, the present invention relates to a method of determining whether a subject suffers from idiopathic steroid sensitive nephrotic syndrome (INS) comprising i) determining the concentration of plasma anti-UCHL1 IgG in a sample obtained from the subject ii) comparing the concentration determined at step i) with a predetermined reference value and iii) concluding that the subject suffer from idiopathic steroid sensitive nephrotic syndrome when the concentration determined at step i) is higher than the predetermined reference value.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Device (12) comprising a multileaf collimator (1), said multileaf collimator comprising an array (2) of leaves (3) and slits (4), said array comprising an alternation of leaves and slits and extending in a longitudinal direction (5), said longitudinal direction being defined as a direction extending from an entrance plane (6) of the array toward an exit plane (7) of the array, each leaf being located between two slits; said device being characterised in that it comprises a source (13) for emitting an incident electromagnetic beam (14) or a source for emitting an incident beam of subatomic particles, said source being arranged to emit the beam in the direction of the entrance plane (6) of the array, said multileaf collimator being arranged to obtain an arrangement of beams (22) from the incident beam, and in that the arrangement of beams (22) forms an alternation of high-energy lines (15) and lower-energy lines (16).

IPC Classes  ?

• G21K 1/02 - Arrangements for handling particles or ionising radiation, e.g. focusing or moderating using diaphragms, collimators
• H05G 1/02 - Constructional details

Abstract

The present invention relates to a method of treating multiple myeloma. The inventors analyzed two sets of 18 and 40 samples from symptomatic t(4; 14) MM at presentation by exome or RNA sequencing, respectively. They confirm the high mutational rates in the NRAS, KRAS, BRAF and FGFR3 genes which have been previously described, and strongly suggests that these events are mutually exclusive in t(4;14) MM. Mutations in ATM/ATR, MAPK and MYCBP2 occur at relatively high frequencies (11.4%, 14% and 8% respectively), while very few t(4;14) patients carry alterations in FAM46C or CCND1. Mutations in PRKD2, the gene coding for the PKD2 serine/threonine kinase, affect around 11.4% of the cases and this alteration is associated with progression to symptomatic myeloma in one patient. The inventors also tested the inhibition of PKD2 activity by kb NB 142-70 and the inhibition of PKD 1, PKD2 and PKD3 by CRT0066101 and observed that these agents induced cell growth arrest and apoptosis of tumor plasma cells in vitro. These results show that PKD2 and others members of the PKD family is a therapeutic target in patients with MM. Thus, the present invention relates to a PKD inhibitor for use in the treatment of multiple myeloma.

IPC Classes  ?

• A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to monoclonal antibodies that bind to the CD160-TM isoform. The inventors developed new monoclonal antibodies which bind to the CD160-TM isoform but dot not bind to the CD160 GPI-anchored isoform not to the CD160 soluble isoform.In particular, the antibodies of the present invention are suitable for amplifying NK cell activation and therefore cytotoxic functions NK cells.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present invention concerns an oil-in-water emulsion consisting of water and an oily phase consisting of lidocaine, a first fatty acid and a second fatty acid, the first fatty acid being lauric acid and/or tridecanoic acid, the second fatty acid being chosen from myristic acid, palmitic acid, stearic acid and oleic acid, and the mixtures of same. These emulsions can be used as medicine, in particular as an analgesic or antalgic in humans or animals, or as a sexual retardant. They can be incorporated into a pharmaceutical or veterinary composition, or into a medical device.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 9/107 - Emulsions
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol

Abstract

The present invention relates to methods and kits for diagnosing alcoholic hepatitis. In particular, the present invention relates to a method of diagnosing alcoholic hepatitis in a subject comprising i) determining the level of at least one cytokeratin-18 fragment in a blood sample obtained from the subject, ii) comparing the level determined at step i) with a predetermined reference value and iii) detecting differential between the level determined at step i) with the predetermined reference value indicates that the subject suffers or does not suffer from alcoholic hepatitis.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to methods and pharmaceutical compositions for the treatment of non-alcoholic fatty liver disease. The inventors showed that autophagy is defective in liver sinusoidal endothelial cells (LSECs) from patients with non-alcoholic steatohepatitis (NASH) and contributes to the main features of this disease. In particular, the present invention relates to a method of treating a non-alcoholic fatty liver disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an agent capable of restoring autophagy in the subject's liver sinusoidal endothelial cells.

IPC Classes  ?

• A01K 67/00 - Rearing or breeding animals, not otherwise provided forNew or modified breeds of animals
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The invention relates to a method for synthesising gold-silver core-shell nanoparticles from an aqueous colloidal solution of gold nuclei with surfactant, the gold-silver core-shell nanoparticles being made from anisotropic gold nuclei, the method comprising adding a silver precursor and a reducing agent to the aqueous colloidal solution of gold in order to deposit silver onto the gold nuclei in a so-called main step, characterised in that the method comprises a step of incubating the aqueous colloidal solution containing the gold nuclei with surfactant in DMSO, before the main step.

IPC Classes  ?

• C30B 7/14 - Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions the crystallising materials being formed by chemical reactions in the solution
• C30B 29/02 - Elements
• C30B 29/60 - Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape characterised by shape

Abstract

The present invention relates to obesity related disease. Identification of patients with nonalcoholic steatohepatitis (NASH) would be useful to counsel them more intensively on diet and lifestyle changes and propose new pharmacological treatments. As a consequence, the inventors worked on a method for post-processing images of a region of interest of the liver for reconstructing a map of the internal magnetic susceptibility by using a Bayesian regularization approach to inverse the internal magnetic field. Such method can be implemented on computer and provides better results than other known methods for obesity related disease. This method may be applied for predicting that a subject is at risk of suffering from such disease, diagnosing a disease, identifying a therapeutic or a biomarker and screening compounds useful as a medicine.

IPC Classes  ?

• G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
• G01R 33/561 - Image enhancement or correction, e.g. subtraction or averaging techniques by reduction of the scanning time, i.e. fast acquiring systems, e.g. using echo-planar pulse sequences
• G01R 33/565 - Correction of image distortions, e.g. due to magnetic field inhomogeneities

Abstract

The present invention aims at improving the Doppler imaging of a biological sample comprising blood. For this, it is proposed a method for imaging a biological sample (10), the sample (10) comprising blood (14) comprising diffusors and solid tissue (16), the method comprising obtaining observation, each observation being characterized by a different point spread function associating a signal to each location of the region of interest, the signal comprising a first contribution representative of the diffusors of blood vessels within the location, a second contribution representative of the tissue diffusors and a third contribution representative of blood signal associated to blood diffusors outside of the location, and estimating, for each location, the blood flow by using a statistical analysis.

IPC Classes  ?

• A61B 8/06 - Measuring blood flow
• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
• G01S 15/89 - Sonar systems specially adapted for specific applications for mapping or imaging
• A61B 8/08 - Clinical applications

Abstract

The invention relates to liver diseases. Liver diseases notably encompass chronic liver disease and liver cancer (a liver primitive cancer or metastasis). There is therefore a need to be able to extract biomarkers for subjects to suffer from this disease. As a consequence, the inventors worked on a method for post-processing images of a region of interest to obtain at least one perfusion parameter and at least one transport parameter. Such method enables to obtain a method which can be implemented on computer and provides access to relevant parameters for liver diseases in an easier and more accurate way. This method may be applied for predicting that a subject is at risk of suffering from such disease, diagnosing a disease, identifying a therapeutic or a biomarker and screening compounds useful as a medicine.

IPC Classes  ?

• G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
• G01R 33/563 - Image enhancement or correction, e.g. subtraction or averaging techniques of moving material, e.g. flow-contrast angiography
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The present invention relates to the use of magnetic resonance imaging in the medical field. One issue addressed by the present invention is the compensating of respiratory movements in the obtained images with magnetic resonance imaging. For this, the method proposes to choose a reference image in the initial set, the determined position for the reference image being a reference position and to compensate the difference between the determined position and the reference position to obtain a corrected set of images for each image of the initial set. Such method can be implemented in a computer and may be used to provide additional functionalities to magnetic resonance imager and renders the taking of images by a magnetic resonance imager easier.

IPC Classes  ?

• G01R 33/565 - Correction of image distortions, e.g. due to magnetic field inhomogeneities
• G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques

Abstract

The field of the present invention is the biotechnology industry, with a scope of use that extends to the health sector, the agricultural industry as well as research. The invention proposes, more particularly, a new method for measuring the thickness of the cell wall in cells having a wall, and its implementation in various fields of use.

IPC Classes  ?

• G01N 15/10 - Investigating individual particles

Abstract

The present invention relates to a novel population of invariant Foxp3+ regulatory T cells, an ex vivo method generating and expanding them and therapeutic uses thereof. The inventors aimed to determine the optimal conditions for inducing Foxp3 expression in invariant Tcells by assessing different nTreg polarizing medium for their capacity to induce the expression the differentiation of Foxp3+ cells with suppressive function. The inventors showed that tumor Ag-specific memory invTCR Vα24+ T cells ex vivo generated and expanded in the presence of the nTreg polarizing medium maintain their ability to perform suppressive function in pro-inflammatory conditions. In particular, the present invention relates to an isolated population of invariant Foxp3+ regulatory T cells having the following phenotype: CD3+ Vα24+ Foxp3+.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to a method for ex vivo generating and expanding MHCII restricted CD4 + Foxp3 + regulatory T cells, and therapeutic uses thereof. The inventors here demonstrated the optimal conditions for inducing Foxp3 expression in naive CD3+ CD4+ TCRαβ+ MHCII restricted T following polyclonal or following antigen-specific activation. They also developed an experimental procedure to generate autologous CD8+ T cell lines functionally committed to lyse tumor-antigen specific FOXP3 expressing TCRαβ+ MHCII restricted T cells, pathogenic CD4+ T cells that favour tumor cell immune evasion. In particular, the present invention relates to a method for generating ex vivo MHCII restricted CD4+ Foxp3+ regulatory T cells having the following phenotype: CD3+ CD4+ Foxp3+.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to therapeutic uses of ex vivo generated Foxp3+ regulatory T cells. The inventors showed the presence of Foxp3+ expressing T cells in tumor infiltrating lymphocytes (TILs) isolated from luminal-B breast cancer. The inventors performed an ex vivo generation and expansion of specific CD3+ TCRy8+ expressing Foxp3: CD3+ TCRy8+ T cells maintain their Foxp3 level and their suppressive activity, after a further 21-day-culture. They also showed that tumor Ag-specific CD3+ TCR Va24+ T cells maintain their ability to perform suppressive function in pro-inflammatory conditions. In particular, the present invention relates to immunotherapeutic uses of at least one of ex vivo generated Foxp3+regulatory T cells population selected among a MHCII restricted CD4+Foxp3+regulatory T cells population, a y8 Foxp3+regulatory T cells population and an invariant Foxp3+regulatory T cells population.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies